Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -46.48% | 58.72% | 125.33% | 124.24% | 206.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.48% | 58.72% | 125.33% | 124.24% | 206.70% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -46.48% | 58.72% | 125.33% | 124.24% | 206.70% |
| SG&A Expenses | 9.49% | -18.53% | -13.02% | -14.09% | -15.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.87% | 10.39% | 42.57% | 17.42% | 28.72% |
| Operating Income | 33.76% | -9.95% | -42.10% | -16.95% | -28.08% |
| Income Before Tax | 39.61% | -24.46% | 168.67% | 12.44% | -33.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.61% | -24.46% | 168.67% | 12.44% | -33.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.61% | -24.46% | 168.67% | 12.44% | -33.18% |
| EBIT | 33.76% | -9.95% | -42.10% | -16.95% | -28.08% |
| EBITDA | 34.17% | -9.88% | -42.45% | -17.18% | -28.85% |
| EPS Basic | 39.23% | -23.85% | 167.08% | 12.72% | -24.86% |
| Normalized Basic EPS | 38.74% | -23.80% | 190.01% | 13.85% | -26.97% |
| EPS Diluted | 39.45% | -25.00% | 165.56% | 10.53% | -27.74% |
| Normalized Diluted EPS | 38.74% | -23.80% | 189.61% | 13.85% | -26.97% |
| Average Basic Shares Outstanding | 0.46% | 0.51% | 0.54% | 0.32% | 0.30% |
| Average Diluted Shares Outstanding | 0.46% | 0.51% | 0.95% | 0.32% | 0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |